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Influenza infection represents a major socio-economic burden worldwide. Novel delivery methods can
render influenza vaccination easier and more acceptable by the public, and importantly confer protection
equal or superior to that induced by conventional systemic administration. An attractive target for vaccine
delivery is the skin. Recent studies have demonstrated improved immune responses after transdermal
delivery of inactivated influenza virus with microneedle patches. Here we show that immunization with a
licensed influenza subunit vaccine coated on metal microneedles can activate both humoral and cellular
arms of the immune response and confer improved long-term protection in the mouse model when
comparedtotheconventionalsystemicrouteofdelivery.Theseresultsdemonstratethepromisingpotential
ofmicroneedledeliveryoflicensedinfluenzasubunitvaccines,thatcouldbebeneficialinincreasingvaccine
coverage and protection and reducing influenza-related mortality worldwide.
I
nfluenza virus is one of the most common pathogens responsible for serious respiratory illness. Typically, the
virus causes seasonal epidemics of influenza with outbreaks in the U.S. ranging from October through April.
During a typical season, the CDC estimates that more than 200,000 hospitalizations, and 40,000 deaths are
associatedwithinfluenzainfectionandrelatedcomplications
1,withupto1.5milliondeathsworldwide
2.Seasonal
influenzainfectionaffectsallagegroupswiththegreatestdiseaseseverityoccurringintheelderly
3–5,personswith
underlying chronic diseases
6,7, infants and young children who have not been previously exposed to the virus
8,
pregnant women
9,10, and health care workers
11.
There are three distinct serotypes of influenza viruses, designated A, B, and C, with types A
12and B
13,14 playing
the major role in human infection. It is well established that the best way of prophylaxis and control of influenza
infection is vaccination, which reduces morbidity and mortality of the disease
15. Currently there are several types
of licensed trivalent influenza vaccines containing 15 mg of hemagglutinin of each H1N1 and H3N2 influenza A
subtypesandoftypeBinfluenzavirus:formalininactivatedwholevirus(WV),ether-treatedhemagglutinin(HA)
and neuraminidase (NA)-enriched split virus (SV) and subunit virus (SU) vaccine which are the most widely
utilized vaccines and are usually administered intramuscularly
16,17.
The immunogenicity of different influenza vaccine formulations was studied in the 1970s; despite the fact that
whole virus was found to be more immunogenic compared to other formulations, its use was discontinued in
most countries and it was replaced with the less reactogenic split or subunit influenza vaccine
18–21. Although the
latter have been proven to be safe, several studies have demonstrated decreased magnitude and longevity of the
immune responses after intramuscular administration especially in high risk groups such as the elderly, immu-
nocompromised individuals and children
22–24. These facts strongly suggest the necessity for new vaccine for-
mulations or new delivery methods that could improve the immune responses, thus reducing morbidity and
mortality from influenza infection worldwide.
The current target for influenza vaccination is the deltoid muscle. However, the muscle tissue contains low
numbers of antigen presenting cells (APCs) such as dendritic cells and macrophages, and lacks MHC class II
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SCIENTIFIC REPORTS | 2 : 357 | DOI: 10.1038/srep00357 1expressing cells leading to poor antigen-dependent T cell activation
and reduced humoral and cellular immune responses
25. Other tissue
targetsfordeliveryofinfluenzavaccinehavebeenproposedinrecent
years including the skin, which represents an ideal target for vaccine
delivery. It contains a large network of immunologically active cells
and APCs that take up the antigen and migrate to the proximal
lymph nodes where naı ¨ve T and B cells will be activated to initiate
the adaptive immune responses
26. We and others have previously
reported that delivery of whole inactivated influenza virus via the
skin using antigen-coated metal microneedle patches elicits strong
humoral and cellular immune responses, serological memory and
improved longtermprotection compared tothe conventionalroutes
of vaccine delivery
25,27,28.
Inthisstudyweinvestigateforthefirsttimetheefficacyofasingle-
doseskinvaccinationwithalicensedinfluenzasubunitvaccineusing
antigen-coated metal microneedles and the longevity of immune
responses induced upon skin delivery.
Results
Humoral immune responses after microneedle or IM delivery
of influenza subunit vaccine. To compare the efficacy of
immunization via the skin or intramuscularly, we first measured
the levels of functional antibody titers against the hemagglutinin
antigen (HA) of influenza virus induced after immunization. The
Centers for Disease Control and Prevention (CDC) state that a
titer of $1540 is indicative of protection in humans. In our
experience titers of $1540 are also indicative or protection in
mice. As shown in Fig. 1a, microneedle delivery of the subunit
vaccine elicited levels of functional antibody titers indicative
of protection (HAI.40) as early as week 4. By week 8 the IM
immunized group exhibited the peak of protective HAI titers
whereas the microneedle group reached the highest levels by week
12.Thirtysixweekspost-immunization,weobservedthat62%ofthe
IM vaccinated animals exhibited protective levels (HAI.40) while
100% of the microneedle group maintained protective levels
of functional antibody titers and two-fold higher titers when
compared to the IM immunized group (p,0.0262). These results
demonstrate that delivery of subunit influenza vaccine through the
skin using microneedles elicits and sustains higher functional
antibody titers, indicative of better duration of protection when
compared to IM immunization.
We additionally determined the levels of influenza-specific cir-
culating IgG antibodies in sera of vaccinated mice. Up to 8 weeks
post-immunization the IM group demonstrated significantly higher
antibody titers than the microneedle group (p,0.0018). From week
12 until week 36 there were no significant differences between the
immunizedgroups(Fig.1b).Inourpreviousstudieswereportedthat
theisotypeprofileoftheimmuneresponsesisaffectedbytherouteof
immunization
25–27. Mice that received the subunit vaccine through
the IM route of delivery exhibited approximately two-fold greater
levels of IgG1 circulating antibodies when compared to microneedle
immunized mice (p,0.0001) (Fig. 1c). In contrast, microneedle
immunization induced a more potent IgG2a response with a two-
fold greater difference when compared to IM injection (p,0.0001)
(Fig. 1d). We found a more balanced IgG1/IgG2a ratio in the micro-
needle group, which skewed towards IgG2a responses at later time
points (Fig. 1e). In contrast the IM immunized group demonstrated a
predominant IgG1 response. These results indicate that microneedle-
based delivery of influenza subunit vaccine induces stronger, long-
lasting IgG2a titers indicative of a Th1 response when compared to
IM immunization.
Delivery of subunit influenza vaccine through the skin using
microneedle or through IM injection induced high levels of neutral-
izing antibody titers in both vaccinated groups. These responses in
the microneedle group were significantly higher than the IM group
at 24 (p50.0426) and 36 weeks post-vaccination (p,0.0002)
(Fig. 1f).These results further demonstrate the stronger immune
responses induced after microneedle delivery of influenza subunit
vaccine in the skin.
Evaluation of systemic recall and mucosal immune responses and
assessment of viral replication after challenge. Twelve weeks after
delivery of a single dose of subunit influenza vaccine, mice from all
groups were challenged with 5xLD50 of mouse-adapted A/Brisbane/
59/2007 virus and 4 days later sera were collected for the evaluation
of recall responses. We observed that the HAI titers were two-
fold higher in the microneedle immunized group than the IM
group (p,0.0195) (Fig. 2a), although there were no significant
differences in the levels of IgG and IgG1 influenza-specific
antibody titers between the vaccinated groups (Fig. 2b, 2c). In
contrast, the levels of influenza-specific IgG2a antibody titers were
significantly higher in the microneedle group when compared to the
IM group (p,0.0223) (Fig. 2d) further indicating a stronger Th1
response induced after skin vaccination. Evaluation of mucosal
immune responses (IgG, IgG1, IgG2a and IgA) in the lungs
of microneedle and IM immunized animals 12 weeks post-
vaccination and 4 days post-challenge did not reveal significant
differences between the two immunized groups (Fig. 3a–d).
In order to evaluate the protective capacity of the immune res-
ponse induced after microneedle or IM delivery of influenza subunit
vaccine, we determined the lung virus titers after challenge at three
months post-vaccination. We were able to detect a high replication
rate of the virus in the IM immunized group with a 1.5-fold decrease
when compared to unimmunized infected animals (Fig. 3e). In con-
trast,micethatreceivedthesubunitvaccinethroughthemicroneedle
route of delivery exhibited 40-fold lower lung virus titers when com-
pared to the IM group. These results demonstrate the induction of
more effective immune responses after microneedle delivery of sub-
unit influenza vaccine in the skin resulting in greater inhibition of
virusreplication andmorerapidclearancefromthelungsofinfected
animals when compared to IM delivery.
Cellular immune responses in the lungs of immunized animals
after lethal challenge. The levels of TNF-a, IL-4, IFN-c, IL-5, IL-6
andIL-10 weremeasured asindicators of cellular immune responses
in the lung suspensions of mice challenged 12 weeks after delivery of
subunit influenza vaccine via microneedle administration or IM
injection. We observed higher TNF-a levels in the unimmunized
infected mice (Fig. 4a) when compared to either group of vac-
cinated animals, representative of the inflammatory process and
cell death in their lungs
25. We measured similar levels of IL-4 in
both microneedle and IM vaccinated groups (Fig. 4b), but these
were elevated when compared to the levels detected in the
unimmunized infected mice. Interleukin-4 inhibits the production
of different pro-inflammatory cytokines including TNF-a. Evalu-
ation of IFN-c, IL-5 and IL-6 levels (Fig. 4c, 4d, 4e) did not reveal
any significant differences between the microneedle and IM vac-
cinated groups. The most notable difference in cytokine pro-
duction was observed in the levels of IL-10 in the microneedle
vaccinated group (Fig. 4f). Interleukin-10 is an important anti-
inflammatory molecule recognized for blocking pulmonary inflam-
mation and lung injury
29. We observed a 2-fold higher level in
IL-10 production levels in microneedle immunized animals when
compared to the IM group (p,0.0026). These results demonstrate
that delivery of subunit influenza vaccine through the skin using
microneedles induces robust cellular immune responses and
increased production of IL-10, correlating with reduced lung
inflammation after lethal challenge.
Evaluation of long-lived bone marrow plasma cells. In order to
further investigate the basis for high serum functional antibody
titers and improved long-lived protective immune responses after
microneedledeliveryofinfluenzasubunitvaccinewhencomparedto
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 357 | DOI: 10.1038/srep00357 2IM immunization, we determined the numbers of influenza virus-
specific IgG long-lived plasma cells in the bone marrow 12 weeks
after a single immunization, a sufficient period for the establish-
ment of memory
30. We detected elevated numbers of-influenza
virus-specific long-lived plasma cells in the bone marrow of both
immunized groups when compared to the naı ¨ve group, and a
significant increase in the numbers of long lived plasma cells in the
microneedle group when compared to IM vaccinated animals
Figure 1 | Evaluation of humoral immune responses and neutralizing antibody titers. Serum samples from mice were collected 2, 4, 8, 12, 24, and 36
weeks post immunization and analyzed for the levels of functional antibody titers against A/Brisbane/59/2007 by HAI (a), total serum IgG titers (b), and
theIgGisotypes, IgG1 (c)and IgG2a(d)by quantitative ELISA, isotype profile ratio(e)andneutralizing antibody titers by microneutralization assay (f).
MN: microneedle immunized group, IM: intramuscularly immunized group. ELISA antibody data represent the mean 6 SEM. HAI data represent the
geometric mean 6 95%CI. *:p ,0.05, **:p ,0.005, ***:p ,0.0001. Statistics for the MN and IM group were performed with two-tailed unpaired
Student’s t-test.
www.nature.com/scientificreports
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number of anti-influenza specific IgA antibody secreting cells in the
bone marrow of microneedle or IM vaccinated groups (Fig. 5b). The
higher numbers of influenza virus-specific long-lived plasma cells
in the bone marrow of microneedle vaccinated animals may be
responsible for the maintenance of high levels of influenza-specific
functional antibody titers in the serum and improved protective
humoral responses when compared to IM delivery of the vaccine.
Determination of IFN-c and IL-4 secreting cells in the spleen. To
comparethe cellular immune responsesinduced after microneedleor
IMdeliveryofsubunitinfluenzavaccine,wedeterminedthe numbers
of IFN-c and IL-4 secreting cells in the spleens of mice 12 weeks after
immunization. We detected significantly higher numbers of IFN-c
secreting cells in the microneedle immunized group when compared
to IM vaccinated animals (p50.0105) (Fig. 6a). However we did not
find any differences between the two immunized groups in the
numbers of IL-4 secreting cells (Fig. 6b). These results indicate
improved cellular immune responses after microneedle delivery of
subunit influenza vaccine compared to IM delivery.
Duration of protective immunity. To evaluate the longevity and
efficacy of subunit influenza vaccine in conferring protection after a
single immunization through the skin or the muscle, cohorts of
vaccinated mice were challenged with 5xLD50 of mouse-adapted
virus at 4, 12 and 36 weeks post-vaccination. Body weight changes
and survival rates were registered daily as previously described
25.
Four weeks post-immunization both vaccinated groups were fully
protectedagainstlethalchallengewithanaveragebodyweightlossof
10–12% (Fig. 7a–a1). Twelve weeks post-immunization both groups
again exhibited full protection against lethal challenge and an aver-
age body weight loss of 5–6% (Fig. 7b–b1). At week 36 post-
immunization, the microneedle group was still fully protected
against the virus challenge, exhibiting an average body weight loss
of5%and100%survival.Incontrast,theIMgroupwasonlypartially
protected with a mortality rate of 40% and an average body weight
loss of 15% for the mice that survived the challenge (Fig. 7c–c1).
These findings demonstrate that skin immunization with micro-
needles coated with an influenza subunit vaccine induces long-
lived immunity capable of conferring full protection and survival
against lethal challenge with the homologous virus at least up to
thirty six weeks after a single immunization.
Discussion
In the present study we report for the first time that microneedle
delivery of a single dose of a licensed influenza subunit vaccine to
Figure 2 | Recall systemic immune responses. The recall humoral immune responses in serum and lung suspensions were determined in MN and IM
immunizedmice12weekspostimmunizationand4dayspost-challenge.Naı ¨veinfected(Inf)andnaı ¨veuninfected(N)micewereusedascontrolgroups.
Serum HAI titers (a), total serum IgG titers (b), and isotype IgG1 and IgG2a profile (c, d). INF: infected mice, N: naı ¨ve mice. ELISA antibody data
represent the mean 6 SEM and the HAI data represent the geometric mean 6 95% CI. *:p ,0.05. Statistics for the MN and IM group were performed
with two-tailed unpaired Student’s t-test.
www.nature.com/scientificreports
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whereas only partial protection was induced after the conventional
IM route of delivery. At the same period microneedle immunization
also induces higher functional antibody titers and higher influenza
specific IgG2a antibodies than the IM immunized group, indicative
of stronger cellular immune responses
25. In our experimental mouse
model, both microneedle and IM immunized groups exhibited sim-
ilar levels of hemagglutination inhibition titers (HAI) at early time
points after immunization. Thirty six weeks later, though, we found
that 38% of the IM immunized animals demonstrated a significant
drop of HAI titers below protective levels (HAI,40), while the
microneedle vaccinated group in its entity retained HAI titers above
protective levels (HAI.40). The maintenance of these high levels of
functional antibody titers throughout a period of nine months can
be attributed to the higher number of influenza-specific antibody
secreting cells (long-lived bone marrow plasma cells) detected in
themicroneedleimmunizedgroupwhencomparedtotheASCnum-
bers found in the IM cohort
25,30.
We have previously reported that skin immunization with whole
inactivatedvirus-coatedmetalmicroneedleswasequalorsuperiorto
systemicvaccination.Inthosestudieswefoundahighanti-influenza
virus IgG1/IgG2a antibody ratio in the microneedle group that
received 10 mg of vaccine indicating a skewed Th2 response. This
response resulted in a two-fold increase of IL-4 production when
compared to the intramuscularly delivered vaccine
26 whereas the
IFN-c production was higher in the IM group than the microneedle
Figure 3 | Recall mucosal immune responses and lung viral titers. Lung IgG (a), IgG1 (b) IgG2a (c) and IgA titers (d). Titers and isotype profiles were
determined by ELISA. Lung viral titers as determined by plaque assay (e). INF: infected mice, N: naı ¨ve mice. Data represent the mean 6 SEM.
www.nature.com/scientificreports
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cells were at similar levels in the bone marrow of both immunized
cohorts. Those data could not clearly favor either route of vaccina-
tionbecausewholeinactivatedvirusvaccinedisplaysstrongerimmu-
nogenicity which can activate both arms of immune responses,
humoral and cellular. In the present study we tested a licensed influ-
enza subunit vaccine as an antigen by metal microneedle delivery
throughtheskinandcomparedittoIMdelivery.Severalstudieshave
previously demonstrated that IM delivery of subunit influenza vac-
cines induces poor cellular immune responses in humans
18. Here we
show that microneedle delivery of a subunit influenza vaccine elicits
higher numbers of IFN-c secreting cells in the spleen of immunized
animals when compared to IM immunization. IFN-c has been
reported to play amajor role in the control of viral infections leading
to faster viral clearance and apoptosis of infected cells
25. Further-
more, while microneedle delivery of whole inactivated virus demon-
strated a robust IgG1 response, and similar numbers of ASC in the
bone marrow, delivery of the subunit vaccine induced a balanced
IgG1 and IgG2a response (ratio51) and higher numbers of ASC in
the bone marrow when compared to IM delivery. These data are
Figure 4 | Cellularimmuneresponsesinlungsuspensionsafterviruschallenge. ThelevelsofTNF-a(a),IL-4(b),IFN-c(c),IL-5(d),IL-6(e)andIL-10
(f)cytokines were measured in lungsuspensions ofMN andIMimmunized animals 12 weeks postvaccinationand 4dayspost-challengewith 5xLD50 of
live virus. INF: infected mice, N: naı ¨ve mice. Data represent the mean 6 SEM. **:p ,0.005. Statistics for the MN and IM group were performed with
two-tailed unpaired Student’s t-test.
www.nature.com/scientificreports
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inactivated virus
27.
Activation of both arms of the adaptive immune response con-
tributes to enhanced protection and rapid virus clearance from the
lungs after infection, as demonstrated by the 40-fold lower virus
titers in the lungs of microneedle immunized mice after lethal
challenge, compared to the titers measured in the IM immunized
mice. This finding can also be significant for influenza transmis-
sion. Influenza vaccines in 90% of vaccinees are delivered by the
intramuscular route. Although vaccinated individuals are pro-
tected from the disease, they are still able to transmit the virus
for a 24–48 hour window
31–33. The greater inhibition of viral rep-
lication and more rapid clearance of the virus observed in the
microneedle immunized group could further reduce the infectious
potential of vaccinated individuals minimizing transmission form
direct contact.
Influenza represents asignificant burden to public health
34–37. The
World Health Organization estimates that there are more than 1.2
billion people at high risk for severe influenza outcomes worldwide:
385 million elderly, 140 million infants and 700 million adults and
children with underlying health conditions including pregnant
women
38. Additionally the WHO estimates that there are approxi-
mately 24 million health care workers at high risk for influenza
infection who pose a risk for transmission of influenza virus to high
risk populations
39. Besides increased health care costs, influenza
infectionposesamajorsocio-economicburdenleadingtohighlevels
ofworkerabsenteeism,disruptioninworkandproductivitylosses.It
is estimated that in the United States, annual influenza epidemics
result in an average of 3.1 million hospitalization days and 31.4
million outpatient visits with an average direct medical cost of 10.4
billion dollars annually
40. Projected lost earnings due to illness and
loss of life averages to 16.3 billion dollars annually, while the total
direct and indirect economic burden of annual influenza epidemics
amount to 87.1 billion dollars in the US alone
40.
Furthermore, the CDC reports that in randomized control trials
amongdifferentagegroupsandindividualswithmedicalconditions,
the inactivated influenza vaccine effectiveness was estimated to be
between 48%–70% during seasons when the vaccine was well
matched with the circulating influenza strains
41. These data indicate
that better influenza vaccines and more effective vaccination meth-
ods are needed that will increase vaccine coverage and reduce mor-
bidity and mortality rates.
The skin represents an attractive target for vaccine delivery. Skin-
based vaccination has received more attention recently due to
encouraging results demonstrating improved immune responses
Figure 5 | Evaluation of bone marrow plasma cells by ELISPOT. The
numbers of influenza-specific IgG (a) and IgA (b) plasma cells in the bone
marrow were determined 12 weeks after a single immunization. The cells
were cultured in the presence of 4 mg/ml purified inactivated A/Brisbane/
59/2007 virus and 18 h later the numbers of plasma cells in the bone
marrow from MN and IM vaccinated mice and unvaccinated infected and
non-infected mice were determined. Plasma cell numbers of vaccinated
micewereconsidered positiveifthenumbers ofspotswerehigherthan the
sum of naı ¨ve infected group spots 1 3xSDev. INF: infected mice, N: naı ¨ve
mice. Data represent the mean 6 SEM. **:p ,0.005. Statistics for the MN
and IM group were performed with two-tailed unpaired Student’s t-test.
Figure 6 | Cellular immune responses in spleen cells. The numbers of
IFN-c (a) and IL-4 (b) secreting cells from the spleen were determined by
ELISPOT. Spleen cells from MN and IM immunized mice and
unvaccinatedinfectedandnon-infectedmicewereculturedinthepresence
of 4 mg/ml purified inactivated A/Brisbane/59/2007 virus for 36 h.
Splenocytes from naı ¨ve mice were stimulated with a typical bacterial super
antigen (SAB) as positive control. INF: infected mice, N: naı ¨ve mice. Data
representthemean6SEM.*:p,0.05.StatisticsfortheMNandIMgroup
were performed with two-tailed unpaired Student’s t-test.
www.nature.com/scientificreports
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25,42–44. Additionally there is evidence for dose
sparing using transdermal immunization
45,46. Several studies have
demonstrated improved immune responses after intradermal deliv-
ery of influenza vaccines
25,44,47,48. We and others have previously
demonstrated that administration of whole inactivated influenza
virus through the skin using solid metal microneedles was capable
of inducing improved immune responses, serological memory and
long-term protection when compared to the conventional routes of
influenza immunization
25,28,49. However the effectiveness of this
route for immunization using a subunit vaccine has not been
investigated previously and the longevity of the immune responses
has received only limited attention.
Here, we used microneedles to simply and reliably deliver influ-
enza subunit vaccine targeted to the skin and we demonstrated
enhanced immune responses when compared to the conventional
systemic route of delivery. Microneedles, therefore, have the poten-
tial to make skin-based vaccination a clinically viable alternative
which, besides the immunologic advantages demonstrated in this
study, offers several logistical advantages including inexpensive
manufacturing, small size for easy storage and distribution, a simple
Figure 7 | Protective efficacy against H1N1 A/Brisbane/59/2007 lethal infection. Body weight changes and survival rates were recorded after lethal
challenge with 5xLD50 of live A/Brisbane/59/2007 virus in MN and IM immunized and naı ¨ve mice 1 month (a–a1), 3 months (b–b1) and nine months
(c–c1) post vaccination. N: naı ¨ve mice. Data represent the mean 6 SEM.
www.nature.com/scientificreports
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patient coverage, and overall better acceptance of this route of vac-
cination by the general public (Kim Y.C. et al Advanced Drug
Delivery Reviews, 2012 in press). Overall, our study demonstrates
that microneedle-based delivery has the potential to be used with
currently approved vaccines and formulations, and for improving
resultswhencomparedtothecurrentconventionalroutes,especially
to generate long-lived protective immunity.
Methods
Microneedlefabricationandcoating.Aspreviouslydescribed
25,metalmicroneedles
were fabricated by etching stainless steel sheets (McMaster-Carr, Atlanta, GA). Each
microneedle measured 700 mm tall, with a cross sectional area of 170 mmb y5 5mma t
the base and tapering to a sharp tip, with five microneedles per row. Microneedles
were dip-coated using a coating solution formulated with 1% (w/v)
carboxymethylcellulose (Carbo-Mer, San Diego, CA), 0.5% (w/v) Lutrol F-68NF
(BASF, Mt. Olive, NJ), 15% (w/v) D-(1)-trehalose dihydrate (Sigma, St. Louis, MO)
and H1N1 A/Brisbane/59/2007 subunit vaccine solution. The vaccine was kindly
provided by Novartis Vaccines and Diagnostics (Cambridge, MA).
Cells and viruses. Madin-Darby canine kidney (MDCK) cells (ATCC CCL 34,
American Type Culture Collection, Manassas, VA) were maintained in Dulbecco’s
Modified Eagle’s Medium(DMEM)(Mediatech, Herndon, VA) containing 10%fetal
bovine serum (Hyclone, ThermoFisher Scientific, Rockford, IL). Influenza virus
stocks (A/Brisbane/59/2007) were prepared, purified and inactivated as previously
described
27. Hemagglutination (HA) activity was determined using turkey red blood
cells (LAMPIRE Biological Laboratories, Pipersville, PA) as previously described
50.
For inactivation, the purified virus was treated with formalin at a final concentration
of0.1%(vol/vol) for48 hat 4uCand thendialyzed againstPBS buffer.Inactivationof
the virus was confirmed by plaque assay in MDCK cells
51. The mouse-adapted virus
was prepared by serial passage 8 times in lungs of BALB/c mice. The LD50 was
calculated by the method of Reed-Muench
52, and viral titers were determined by
plaque assay.
Immunizations, lethal challenge and sample collection. Female BALB/c mice
(Charles River Laboratory, Wilmington, MA) (50 mice per group, 6–8 weeks old)
received one dose (3 mg) of the subunit A/Brisbane/59/2007 vaccine through the skin
usingmicroneedlearrayscoatedwiththeantigenorbyIMinjection.Formicroneedle
delivery the mice were vaccinated by manual insertion of the microneedles into the
skin on the dorsal surface for 5 min while for IM immunization mice received an
equal dose of the vaccine in both legs
25. Unimmunized mice were used as an
additional negative control. Animals were bled retro-orbitally 2, 4, 8, 12, 24 and 36
weeks post-immunization under systemic anesthesia. Four, 12 and 36 weeks
following immunization, mice (n55) were challenged with 5xLD50 dose of live
mouse-adapted H1N1 A/Brisbane/59/2007 virus and were monitored for 14 days for
signs of morbidity (body weight changes, fever and hunched posture) and mortality.
A weight loss exceeding 25% was used as the experimental end point, at which mice
were euthanized according to IACUC guidelines. All animal studies had approval of
Emory University’s Institutional Animal Care and Use Committee. Twelve weeks
post-immunization and four days post-challenge of an independent cohort of
microneedle and IM vaccinated groups, blood was collected by retro-orbital bleeding
with non-heparinized microcapillary tubes (Fisher Scientific, Pittsburg, PA). Lungs
were collected in DMEM at 12 weeks, 4 days post-lethal challenge and processed as
previously described
27. All serum samples and lung homogenates were individually
processedtodeterminehumoralimmuneresponses
26.Lungsupernatantsweremixed
with the protease inhibitor phenylmethylsulfonyl fluoride (1 mM) (Sigma, St. Louis,
MO)andstoredat280uCuntilassayedforviraltitersorcytokinelevelswithcytokine
ELISA. Spleens were collected for the evaluation of cellular immune responses and
processed into single cell suspensions in complete RPMI 1640 for cytokine
determination
53. Bone marrow was collected and processed in single cell suspension
for the determination of influenza-specific IgG and IgA antibody secreting cells
(ASC) as previously described
25.
Evaluation of humoral immune responses. All sera and lung suspensions were
individuallyprocessed,andanti-influenzaspecificIgG,IgG1,IgG2aandIgAantibody
levels were determined quantitatively by enzyme-linked immunosorbent assay
(ELISA) as previously described
53. Purified mouse IgG, IgG1, IgG2a, IgA and goat
anti-mouse-HRPforELISAwerepurchasedfromSouthernBiotechnologyAssociates
(Birmingham, AL). Optical density was read at 490 nm.
Hemagglutination inhibition (HAI) titers were determined based on the WHO
protocol
54 as described previously
51. Sera were pre-treated with receptor-destroying
neuraminidase (RDE) (Roche Diagnostics, Indianapolis, IN). The HAI titer was read
as the reciprocal of the highest dilution of serum that conferred inhibition of
hemagglutination. The values were expressed as the geometric mean 1/2 standard
error of the mean. Virus microneutralization assay was performed as described
elsewhere[CDCInfluenzamanualRev06FEB98]withmodifications.Briefly,50mlof
virus diluent containing 100 xTCID50 of each virus was incubated with 50 mlo f
serially diluted heat-inactivated sera at 37uC for 1 h, and then mixed with 100 mlo f
freshly trypsinized low-passage MDCK cell suspension (ATCC # CRL-2936)
containing 5310
4 cells in 96-well tissue plates. The controls wells contained cells
alone (negative control) and cells infected with virus (positive control). Following an
18 – 22 h incubation period the cells were fixed with acetone and the infected wells
were detected by ELISA. Mouse monoclonal biotinylated anti-NP antibody
MAB8257B (Millipore, Temecula, CA), dilution 153,000, and HRP-streptavidin
conjugate (BD # 51-9000209, BD Biosciences, San Jose, CA), dilution 154,000 were
used in the ELISA. Color was developed using OPD substrate (#002003 Invitrogen,
Frederick, MD) and optical density was measured at 490 nm in plate reader (model
680BioRad,Hercules,CA).Thehighestserumdilution thatgenerated .50%specific
signalwasconsideredtobetheneutralizationtiter;50%specificsignal5(OD490virus
control -OD490 cell control)/2 1OD490 cell control.
Measurementoflungviraltitersafterchallenge.Todeterminethetitersofinfluenza
virus in the lungs of immunized mice after challenge, the animals of each group were
infected with 5xLD50 3 months after vaccination and were sacrificed on day 4 post-
infection. Naı ¨ve mice and unimmunized mice infected with 5xLD50 were used as
control groups. Lung homogenates were prepared in DMEM serum-free medium to
assess the viral titers per gram of tissue by plaque assay as described
25 and the LD50
was determined in the same mouse strain and calculated with the Reed-Muench
formula.
Evaluation of cellular immune responses. Cellular immune responses were
estimated using ELISPOT assays in the spleens and cytokine ELISA in the lung
suspensions. Freshly isolated splenocytes (1.0310
6/200 ml cRPMI) were cultured for
48 h in the presence of 4 mg/ml whole inactivated influenza virus in cRPMI 1640
medium
26.IL-4and IFN-cELISPOTreagentswere purchased fromBD-PharMingen
(San Jose, CA). Colored spots were visualized and counted using an ELISPOT reader
and counter (Cellular Technologies, USA). Lung supernatants in DMEM prepared
from immunized mice on day 4 post-challenge were assayed for TNF-a, IFN-c, IL-4,
IL-5, IL-6 and IL-10 according to the manufacturer’s instructions (eBioscience, San
Diego, CA)
27.
Quantification of anti-Brisbane/59/07 antibody secreting cells. Virus-specific
antibody-secreting cells (ASC) in the bone marrow were determined by a
modification of the ELISPOT assay
30,55. Briefly, 96-well plates were coated overnight
at 4uC with purified inactivated A/Brisbane/59/07 at a final concentration 4 mg/ml.
TheplateswerewashedthreetimeswithRPMIandblockedfor2 hwith10%fetalcalf
serum prior to sample addition. Bone marrow single cell suspensions collected at 4
days after challenge (1310
6/well) in cRPMI were plated directly on coated blocked
plates and were incubated at 37uC for 18 h
26. Samples were enumerated in an
ELISPOTreader(CellularTechnology,ShakerHeights,OH)andtheresultsshownas
the number of ASC per 10
6 cells. Plasma cell numbers of vaccinated mice were
consideredpositiveifthenumbersofspotswerehigherthanthesumofnaı ¨veinfected
group spots 1 3xSDev.
Statistics. The statistical significance of the differences was calculated by two-tailed
unpaired Student’s t-test and one-way ANOVA (one–way analysis of variance
includingBonferroni’smultiplecomparisontest)ortwo-wayANOVA.Forstatistical
designations in the figures, * denotes p,0.01; ** denotes p,0.005 and ***denotes
p,0.0001. Unless otherwise stated, independent experiments were run at least in
triplicate.
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